<DOC>
	<DOCNO>NCT00994123</DOCNO>
	<brief_summary>A Phase 1-2 study MM-121 combination standard therapy non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study MM-121 Combination Therapy Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Phase 1 : Patients Non-Small Cell Lung Cancer ( NSCLC ) may enrol evaluate safety , tolerability recommend Phase 2 dose MM-121 combination standard therapy . Phase 2 : Patients Non-Small Cell Lung Cancer ( NSCLC ) may enrol estimate progression-free survival MM-121 + standard therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients locally advance metastatic nonsmall cell lung cancer . Patients must &gt; /= 18 year age . Patients must adequate Performance Status ( PS ) measure ECOG adequate end organ function . Patients recent history ( within 5 year ) another malignancy . Patients pregnant nursing . Patients clinically significant heart failure . Patients clinically significant eye gastrointestinal abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
	<keyword>Metastatic Non-Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
	<keyword>MM-121</keyword>
	<keyword>ErbB3</keyword>
	<keyword>Her3</keyword>
	<keyword>Epidermal Growth Factor Receptor</keyword>
	<keyword>anti-ErbB3 human monoclonal antibody</keyword>
	<keyword>ErbB3 antagonist</keyword>
</DOC>